An observational study in Retinal Dystrophies, Retinitis Pigmentosa and Glaucoma, sponsored by Sheba Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-25.
Sponsored by Sheba Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Retinitis Pigmentosa with a site in Israel — 5 open to participants now, 9 under way, 1 of them phase 3. Retinitis Pigmentosa · Israel.
Among the 14 studies in Retinitis Pigmentosa with a site in Israel, this one is the only one that started in 2013, is one of 6 observational ones, and was the 5th registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →5 of the 14 studies in Retinitis Pigmentosa with a site in Israel are open now. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in Israel, United States, Australia and 11 more countries
Ages 4+
Hadassah Medical Organization · Sites in Israel
Ages 18+ · Healthy volunteers
Sheba Medical Center · Sites in Israel
Ages 18+
Sheba Medical Center · Sites in Israel
Ages 12–18
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2013.
This study's planned enrollment of 200 is above the median of 52 across 87 observational studies indexed under Retinitis Pigmentosa.
Median enrollment 46 across the 8 interventional studies, 112 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 5 most frequent:
Sheba Medical Center is the lead sponsor of 678 studies on the registry; 63 are open to participants now.
Sheba Medical Center has 6 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
2 of the studies in Retinitis Pigmentosa with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02014389Sheba Medical CenterEvaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer | 2026-12-31 |
| NCT04765345Jaeb Center for Health ResearchRate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Retinitis Pigmentosa with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Objective perimetry can better monitor visual field defects in retinal dystrophy and Glaucoma patients than conventional subjective perimetry. The PLR ( Pupil Light Reflex to short and long wavelength stimuli should be significantly lower compared to healthy participants in areas of visual field defects in retinal dystrophy and Glaucoma patients.
Pupil light reflex (PLR) will be measured by a chromatic multifocal pupillometer in response to short and long wavelength light with small spot stimulus in 76 points of the 30 degree visual field.
A computerized infrared video pupillometer will be used to record changes in pupil diameter in response to short- and long-wavelength stimuli (peak 485 nm and 620 nm, respectively) presented by 76 LEDs, 1.8mm spot size, at light intensities of 10-3000 cd/m2 and duration of 1-3 sec at different points of the 30 degree visual field
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
This study's planned enrollment of 200 is above the median of 52 across 87 observational studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Sheba Medical Center is the lead sponsor of 678 studies on the registry; 63 are open to participants now.
Compared within Retinitis Pigmentosa, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Retinal Dystrophies. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Two Groups: 1. Control, 2. Patients - Glaucoma patients with early damage (nasal step) of Humphrey visual field (HVF), Glaucoma patients with advanced damage of HVF (arcuate , tubular vision) and retinal dystrophy patientsl
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects will be used as control group
Patients with Glaucoma , Patients with retinal dystrophy
PLR response amplitude and latency
Time frame: single visit
Started Dec 2013 (actual). Primary completion is estimated for Dec 2026, 156 months after the start.
Of 48 observational studies under Retinitis Pigmentosa, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 28. This study's planned 156 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.